Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy.


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
23 11 2022
Historique:
entrez: 23 11 2022
pubmed: 24 11 2022
medline: 26 11 2022
Statut: ppublish

Résumé

The tumor-intrinsic NOD-, LRR- and pyrin domain-containing protein-3 (NLRP3) inflammasome-heat shock protein 70 (HSP70) signaling axis is triggered by CD8

Identifiants

pubmed: 36417489
doi: 10.1126/scitranslmed.abq7019
pmc: PMC10347419
mid: NIHMS1905126
doi:

Substances chimiques

Toll-Like Receptor 4 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
HSP70 Heat-Shock Proteins 0
TLR4 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

eabq7019

Subventions

Organisme : NCI NIH HHS
ID : F32 CA247067
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA249085
Pays : United States

Références

Cancers (Basel). 2021 Jan 15;13(2):
pubmed: 33467713
BMC Cancer. 2018 May 2;18(1):500
pubmed: 29716544
Cancer Immunol Res. 2015 Sep;3(9):1082-95
pubmed: 26041736
Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.2
pubmed: 18432775
Cancers (Basel). 2021 Sep 23;13(19):
pubmed: 34638239
FASEB J. 2013 Apr;27(4):1631-43
pubmed: 23254341
Nat Commun. 2022 Mar 25;13(1):1606
pubmed: 35338135
Circ Res. 2001 Jul 6;89(1):20-5
pubmed: 11440973
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):
pubmed: 33649199
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008
pubmed: 31028147
Immunity. 2018 Jan 16;48(1):147-160.e7
pubmed: 29343435
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
J Clin Invest. 2020 May 1;130(5):2570-2586
pubmed: 32017708
Cell Rep. 2015 Nov 3;13(5):898-905
pubmed: 26565903
Anticancer Res. 2005 Nov-Dec;25(6B):3905-15
pubmed: 16312045
PLoS One. 2012;7(9):e46076
pubmed: 23049940
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762
pubmed: 30361681
Sci Immunol. 2020 Jan 3;5(43):
pubmed: 31901074
J Biol Chem. 2010 Feb 26;285(9):6477-88
pubmed: 20038581
Clin Oncol (R Coll Radiol). 2022 Jan;34(1):e18-e24
pubmed: 34563446
Clin Cancer Res. 2019 Feb 1;25(3):989-999
pubmed: 30206165
Theranostics. 2021 Oct 17;11(20):9884-9903
pubmed: 34815793
Nat Commun. 2013;4:1853
pubmed: 23673638
Nature. 2010 Aug 12;466(7308):869-73
pubmed: 20668451
Eur Respir J. 2020 Feb 20;55(2):
pubmed: 31744834
Clin Cancer Res. 2020 Apr 15;26(8):1846-1855
pubmed: 31757877
Immunity. 2009 Jun 19;30(6):875-87
pubmed: 19501000
Cancer Cell. 2016 Nov 14;30(5):668-681
pubmed: 27846389
J Clin Med. 2021 Nov 22;10(22):
pubmed: 34830742
Cancer Cell. 2016 Aug 8;30(2):243-256
pubmed: 27505671
Curr Protoc Immunol. 2018 Nov;123(1):e58
pubmed: 30238640
Front Immunol. 2021 Aug 31;12:661323
pubmed: 34531850
Nature. 2005 Dec 8;438(7069):820-7
pubmed: 16341007
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Cancer Immunol Res. 2018 Dec;6(12):1459-1471
pubmed: 30209062
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250
pubmed: 28351930
Cancer Immunol Immunother. 2022 Mar;71(3):579-588
pubmed: 34278517
Cell. 2013 Feb 28;152(5):1173-83
pubmed: 23452860
PLoS One. 2011;6(9):e24370
pubmed: 21931695
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Front Oncol. 2021 Sep 24;11:756365
pubmed: 34631593
Oncol Rep. 2016 Apr;35(4):2053-64
pubmed: 26782741
Cell. 2016 Dec 1;167(6):1540-1554.e12
pubmed: 27912061
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
Front Immunol. 2019 Feb 07;10:172
pubmed: 30792719
Nat Rev Immunol. 2019 Aug;19(8):477-489
pubmed: 31036962
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
J Exp Med. 2021 Oct 4;218(10):
pubmed: 34477811
Nat Rev Clin Oncol. 2019 Oct;16(10):601-620
pubmed: 31160735
Mol Cancer. 2018 Nov 17;17(1):158
pubmed: 30447690
J Immunol. 2016 Aug 1;197(3):859-71
pubmed: 27307558
J Clin Immunol. 2019 Apr;39(3):277-286
pubmed: 31077002
Nat Cell Biol. 2008 Nov;10(11):1349-55
pubmed: 18820689
JAMA Oncol. 2018 Nov 1;4(11):1543-1552
pubmed: 30193240
Am J Physiol. 1998 Oct;275(4):L687-93
pubmed: 9755100
Tumour Biol. 2014 Jan;35(1):545-51
pubmed: 23949880

Auteurs

Balamayooran Theivanthiran (B)

Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.

Nagendra Yarla (N)

Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.

Tarek Haykal (T)

Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.

Y-Van Nguyen (YV)

Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.

Linda Cao (L)

Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.

Michelle Ferreira (M)

Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.

Alisha Holtzhausen (A)

Lineberger Comprehensive Cancer Center, University of North Caroline at Chapel Hill, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Rami Al-Rohil (R)

Department of Pathology, Duke Cancer Institute, Duke University Durham, Durham, NC 27710, USA.

April K S Salama (AKS)

Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.

Georgia M Beasley (GM)

Department of Surgery, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.

Michael P Plebanek (MP)

Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.

Nicholas C DeVito (NC)

Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.

Brent A Hanks (BA)

Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.
Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27708, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH